Search 

Enesi Pharma is developing next-generation vaccination products, targeting infectious diseases and emergent threat pathogens, enabled by its ImplaVax® technologies. These diseases affect millions of people around the world. We work in partnership with global companies, government agencies, leading academic institutions and non-governmental organisations with the goal of making a material and lasting positive impact on global health.

Our award-winning ImplaVax®-enabled vaccination products leverage our innovative unit solid-dose formulation and needle-free delivery technologies and are applicable across all vaccine formats. ImplaVax® products are designed to enhance the immune response and offer significant benefits for patients, care givers, healthcare professionals and payers through enhanced effectiveness, safety, ease of use, reliability and stability, and a strong subject preference over administration using needle and syringe. They can be administered with minimal training and are also rapidly deployable while eliminating the need for cold-chain storage.

Our pipeline targets a range of common and emerging infectious diseases, inflammatory diseases and allergies, and has been established through collaborations with world-class organisations, including BARDA DRIVe*, the Bill & Melinda Gates Foundation, Innovate UK, the University of Oxford, the Walter Reed Army Institute of Research (WRAIR), Sementis, the University of Adelaide and Imperial College London. Our recently announced collaboration with Pirbright is one of a number of developing collaborations in animal health.

The mission of Gemseki Inc. is “We strive to make contributions to humanity and society by supporting the best development of valuable drug candidates.”

We position ourselves as a portal platform company, by providing the Drug Candidate Marketplace platform, to support the best use of hidden and untapped drug candidates by bridging companies who would like to introduce and/or license-out their drug candidates and companies who are eager to license-in the knowledge of these candidates to develop valuable new drugs.

By providing our services, we sincerely hope that valuable new drugs are made available to the society in efficient and timely manner, leading to countless amounts of patient’s lives to be saved.

All members of Gemseki Inc. strive and commit ourselves in making the sincere daily effort of turning hidden and untapped drug candidates (gemstones) into valuable new drugs (brilliant gems). I look forward to being able to share this new exciting endeavor and progress with you all, and am always grateful for your continued support.

Consistently rated in the top 10 universities in the world, Imperial College London is the only university in the UK to focus exclusively on science, medicine, engineering and business.

At Imperial we bring together people, disciplines, industries and sectors to further our understanding of the natural world, solve major engineering problems, lead the data revolution and improve health and well-being.

Isogenica develops LlamdA® VHH: highly versatile small format antibodies which we use to construct next generation biotherapeutics for the treatment of cancer, inflammation and other serious diseases. LlamdA® VHH can be assembled to create bispecific and multi-specific biotherapeutics, or used to achieve targeted drug delivery as components of ADCs and cell and gene therapies including CAR-Ts.

Kinomica is a pioneering precision medicine research and diagnostics company specialising in cell signalling with an interdisciplinary phosphoproteomics platform that combines LC–MS/MS with advanced proprietary bioinformatics to provide bespoke R&D and diagnostic services.

LSX is a growing influential community of senior life science decision makers. We are a catalyst for dialogue, debate and deal making to help lead growth in healthcare investment and the building of billion pound healthcare businesses. We are determined to forge a fundamentally better way to promote and facilitate investment, financing, partnerships and deal making in healthcare.

Our community helps catalyse early stage innovation through peer-to-peer education and knowledge sharing, networking, partnering and deal making to champion the most innovative and exciting ideas. We bring deals to life.

Mawdsleys are a UK based pharmaceutical wholesaler and leading partner to the healthcare sector and pharmaceutical industry. They offer a range of services:

Pharmaceutical Industry:-
Pharma Third Party Logistics (3PL)
Named Patient Medicine Distribution
Clinical Trial Logistics (inc. blinding, randomisation, labelling, global distribution)
Clinical Trial Materials sourcing & manufacture (inc. IMPs, placebos, over encapsulation)
Regulatory Affairs Services (inc. QP Release / batch certification, QP Services, RP Services)
Patient Information Testing

Healthcare Sector:-
Wholesale Services to hospitals
International Sales
Unlicensed / Named Patient Medicine Supply
Clinical Trial Supply to hospitals and academia (inc. placebos)
Pharmaceutical Overlabelling
Pharmacy IT systems

MedCity is the life sciences cluster organisation for London and the greater south east of England, set up in 2014 by the Mayor of London and the region’s three Academic Health Science Centres. We are funded by the Greater London Authority and Research England, and as a not-for-profit are able to act as a neutral and independent convener across industry, academia and the public sector.

London and the greater south east is home to a rich life sciences cluster, with more than 3,400 life sciences companies, four of the world’s top ten universities, 19 of the top 20 global pharmaceutical companies and world class research centres including The Francis Crick Institute, Harwell Oxford and The Sanger Institute.

Our ambition is for our region to be the unequivocal place of choice for world-leading health and life sciences innovation, R&D, manufacture and commercialisation.

Mereo BioPharma is a UK-based international biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for people in both oncology and rare diseases. Mereo's lead oncology product candidate, etigilimab (Anti-TIGIT) has completed a Phase 1a dose-escalation clinical trial in patients with advanced solid tumors and has been evaluated in a Phase 1b study in combination with nivolumab in select tumor types. Mereo's rare disease product portfolio consists of setrusumab, which has completed a Phase 2b dose-ranging study in adults with osteogenesis imperfecta (OI), as well as alvelestat, which is being investigated in a Phase 2 proof-of-concept clinical trial in patients with alpha-1 antitrypsin deficiency (AATD) and in a Phase 1b/2 clinical trial in COVID-19 respiratory disease.

Midatech Pharma is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. Driven by a team of scientists, engineers, and pharmaceutical development specialists, and led by an experienced management team, Midatech is progressing a pipeline of differentiated therapeutics in areas of high unmet need for the benefit of patients.